The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL ...

The 2025 pharmaceutical pipeline is expanding with generics, biosimilars, and new therapies, despite delays from patent ...

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

The future treatment landscape for follicular lymphoma is being rapidly shaped by several promising agents and novel ...

The top 5 infectious disease stories on AJMC.com this year covered both outbreaks and government-related developments. Bird ...

Remote therapeutic monitoring (RTM) of patients with blood cancers cut hospitalizations from infections by 52% over 2 years ...

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both ...

“In support to recent literature in arrhythmogenic cardiomyopathy, our cohort data showed that the protective effect of a negative genetic testing on disease progression was a stronger predictor than ...

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

Conclusions: Two-stage HRSN screening based on geography is suboptimal. Although a 2-stage approach based on area-level socioeconomic measures can reduce the number of patients requiring ...

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza. A nationwide Danish cohort study reports cardiovascular events ...